According to Diane Feller, a Park Nicollet clinician who specializes in menopause, a new position statement on hormone therapy was recently released from the North American Menopause Society (NAMS). The 2017 statement shows recommendations have shifted towards a more favorable view about the use of hormone therapy (HT) for menopause. Below is the full statement.
Listen to our upcoming November interview on our podcasts with Diane Feller from the Park Nicollet Women’s Center as we discuss symptoms, concerns and more about hormone therapy during the menopause years.
Diane is a Certified Nurse Midwife who received additional training to become a Certified Menopause Practitioner through the North American Menopause Society (NAMS).
The 2017 Hormone Therapy Position Statement from the
North American Menopause Society (NAMS)
NAMS released a 2017 position statement which updates their 2012 statement and recommendations on hormone therapy. This statement provides evidence-based and current best clinical practice recommendations about the use of hormone therapy (HT) for treatment of menopause-related symptoms, and reviews the effects of HT on various health conditions at different stages of a woman’s life.
In summary, hormone therapy:
- Remains the most effective treatment for vasomotor symptoms (VMS) – hot flashes and night sweats
- Remains the most effective treatment for the Genitourinary Syndrome of menopause (GSM) – changes to the vagina, vulva and bladder due to the decrease of estrogen and other hormones
- Has been shown to prevent bone loss and fracture
The risks of HT differ depending on type, dose, length of use, how HT is taken, age when started and whether a progestogen is used. “Treatment should be individualized to identify the most appropriate HT type, dose, formulation, route of administration and duration of use, using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation of the benefits and risks of continuing or discontinuing HT.”
The effect of severe menopause symptoms on one’s quality of life may be substantial. Desire for improved quality of life may cause women and providers to accept a greater degree of risk to obtain significant improvement.
“For healthy symptomatic women aged younger than 60 years or who are within 10 years of menopause onset, the more favorable effects of HT on coronary heart disease and all-cause mortality should be considered against potential rare increases in risks of breast cancer, blood clot (venous thromboembolism or VTE) and stroke.”